Despite financial constraints, AIM ImmunoTech Inc (AIM) progresses with promising clinical trials and strategic leadership ...

The PGIM Jennison Rising Dividend Fund declined for Q4 2024 and underperformed the 2.4% return of the S&P 500 Index. Click ...

Q4 2024 Earnings Call Transcript April 1, 2025 Operator: Hello and welcome to the AIM ImmunoTech Fourth Quarter and Full Year ...

Q4 2024 Earnings Call Transcript March 27, 2025 Innate Pharma S.A. misses on earnings expectations. Reported EPS is $-0.33474 ...

Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ETCompany ParticipantsAdanna Alexander – IRPhillip Chan - ...

We will begin the MacroGenics fourth quarter and full year 2024 corporate progress and financial ... not including any of the indications where AstraZeneca is developing their PD-1, CTLA-4 bispecific.

For this article, we used a Finviz screener to filter all the available ADR stocks. Then we compare the list with our Q4 2024 ...